Cargando…

Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’

Detalles Bibliográficos
Autores principales:	Ji, Dong, Xu, Jing, Qin, Enqiang, Zhang, Dawei, Cheng, Gregory, Wang, Yudong, Lau, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200372/ https://www.ncbi.nlm.nih.gov/pubmed/32387073 http://dx.doi.org/10.1016/j.jhep.2020.04.039

Ejemplares similares

No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease
por: Biquard, Louise, et al.
Publicado: (2020)

Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study
por: Ji, Dong, et al.
Publicado: (2020)

Letter to the Editor: Obesity, diabetes, non-alcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease are proinflammatory hypercoagulable states associated with severe disease and thrombosis in Covid-19
por: Ji, Dong, et al.
Publicado: (2021)

Reply to: ‘Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis’
por: Ji, Dong, et al.
Publicado: (2020)

Effect of COVID-19 on patients with compensated chronic liver diseases
por: Ji, Dong, et al.
Publicado: (2020)

Reply to: “Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!”
por: Rabinowich, Liane, et al.
Publicado: (2022)

Reply to: ‘NAFLD or comorbidities, that is the question’
por: Ji, Dong, et al.
Publicado: (2020)

Comments on Relationship between the High Fatty Liver Index and Risk of Fracture: Reply
por: Kim, Min-Ji, et al.
Publicado: (2023)

Reply to: “NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues”
por: Ji, Dong, et al.
Publicado: (2021)

Reply to: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)
por: López-Mendez, Ivan, et al.
Publicado: (2021)

Reply to “Ample evidence suggests SARS-CoV-2 triggers polyradiculitis”
por: Esteban Molina, A., et al.
Publicado: (2022)

Reply to “Ample evidence suggests SARS-CoV-2 triggers polyradiculitis”
por: Esteban Molina, A., et al.
Publicado: (2022)

Reply to: Correspondence relating to “SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19”
por: Wang, Yijin, et al.
Publicado: (2020)

Lack of genetic evidence that fatty liver disease predisposes to COVID-19
por: Valenti, Luca, et al.
Publicado: (2020)

Acute Fatty Liver of Pregnancy
por: Dey, Madhusudan, et al.
Publicado: (2012)

Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19
por: Targher, G., et al.
Publicado: (2020)

Utilization of SARS-COV-2 positive donors and recipients for liver transplantation in the pandemic era – An evidence-based review
por: Agrawal, Dhiraj, et al.
Publicado: (2022)

Reply to the comments of Naharci et al. on “Circulating level of fatty acid‐binding protein 4 is an independent predictor of metabolic dysfunction‐associated fatty liver disease in middle‐aged and elderly individuals”
por: Tanaka, Marenao, et al.
Publicado: (2022)

In Reply—Repeated Testing in SARS-CoV-2 Infection
por: Shah, Aditya, et al.
Publicado: (2020)

Reply to “Intensification of an Essential Tremor by SARS-CoV-2”
por: Passaretti, Massimiliano, et al.
Publicado: (2022)

Authors’ Reply to ‘Pyogenic Liver Abscess and Risk of Acute Pancreatitis’
por: Lai, Shih-Wei, et al.
Publicado: (2015)

Reply to: “Liver tests abnormalities in COVID-19: trick or treat?”
por: Cai, Qingxian, et al.
Publicado: (2020)

Metabolic Phenotypes: Drivers of Health Outcomes in Fatty Liver Diseases
por: Charatcharoenwitthaya, Phunchai
Publicado: (2023)

The present evidence summary of SARS-CoV-2 vaccine-associated liver injury: A rapid systematic review
por: Li, Zheng, et al.
Publicado: (2023)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

Reply to: “Clinical characteristics of COVID-19 patients with abnormal liver tests”
por: Cai, Qingxian, et al.
Publicado: (2020)

Reply to: “Association of chronic liver disease with the prognosis of COVID-19 patients”
por: Mallet, Vincent, et al.
Publicado: (2022)

Reply to: “COVID-19-associated liver injury (COVALI): role of hepatologists”
por: Li, Dongxiao, et al.
Publicado: (2021)

Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis
por: Pan, Lu, et al.
Publicado: (2021)

Liver injury after mRNA-based SARS-CoV-2 vaccination in a liver transplant recipient
por: Dumortier, Jérôme
Publicado: (2022)

The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients
por: Freitas, Marta, et al.
Publicado: (2022)

Is SARS-CoV-2 associated with liver dysfunction in COVID-19 patients?
por: Ali, Nurshad
Publicado: (2020)

SARS-CoV-2: Is the liver merely a bystander to severe disease?
por: Bangash, Mansoor N., et al.
Publicado: (2020)

SARS-CoV-2 related liver impairment – perception may not be the reality
por: Philips, Cyriac Abby, et al.
Publicado: (2020)

Unexplained liver test elevations after SARS-CoV-2 vaccination
por: Guardiola, John, et al.
Publicado: (2022)

Reply to “The SARS-COV Pandemic Does Not Absolve From Solid Medical Trade”
por: Okor, Ivana, et al.
Publicado: (2021)

Reply to: “Combined heart-liver transplantation for congestive hepatopathy with bridging fibrosis: Is it warranted?”
por: Allaire, Manon, et al.
Publicado: (2021)

Reply to: Comments on “Association of liver abnormalities with in-hospital mortality in patients with COVID-19”
por: Ding, Ze-yang, et al.
Publicado: (2021)

Liver- Heart Inter- Relationship in Fatty Liver Disease Based on the Avicenna’s Point of View
por: KHADEM, Ebrahim, et al.
Publicado: (2013)

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bo2j4up84u5qai41psoslrcq7s